Fibroblast-derived Spondin-2 promotes dysplastic transition in metaplastic gastric epithelial cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42641992.
- Also identified by DOI 10.1053/j.gastro.2026.08.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fibroblasts are increasingly recognized as active drivers of early gastric carcinogenesis, yet the specific fibroblast-derived factors that promote the transition from metaplasia to dysplasia remain unknown. We have recently found that coculture of metaplasia or cancer-derived fibroblasts with gastroids dominated by spasmolytic polypeptide-expressing metaplasia (SPEM) lineages leads to a decrease of metaplastic markers and a concomitant up-regulation of dysplasia markers. We have now identified the matricellular protein Spondin-2 (SPON2) as a key fibroblast-secreted mediator of this transition. Single-cell RNA-sequencing of patient-derived fibroblast populations and proteomic profiling of conditioned media were used to identify fibroblast-secreted factors. Spatial transcriptomics was used to evaluate localization of SPON2+ fibroblasts in human gastric tissue. Knockdown of SPON2 in cancer-derived fibroblasts was performed in coculture with SPEM lineage gastroids, and recombinant SPON2 treatment was applied to metaplastic gastroids. Single-cell RNA-sequencing and proteomic profiling revealed SPON2 as the most upregulated and selectively secreted protein in metaplasia- and cancer-derived fibroblasts compared to normal fibroblasts. Spatial transcriptomics demonstrated PDGFRA/SPON2 co-expressing fibroblasts localized adjacent to metaplastic glands in human gastric tissue. Knockdown of SPON2 in cancer-derived fibroblasts abrogated induction of dysplastic promotion in cocultured SPEM lineage gastroids, while preserving metaplastic markers. Conversely, recombinant SPON2 treatment promoted down-regulation of metaplastic markers and upregulation of dysplasia-associated proteins in metaplastic gastroids. Following cessation of SPON2 treatment, gastroid cells lost their dysplastic markers and regained metaplastic markers. These findings identify fibroblast-derived SPON2 as a potent secreted factor driving the metaplasia-to-dysplasia transition in gastric epithelium. Therefore, SPON2 represents the first fibroblast-derived secreted factor that can promote pre-neoplastic progression.